BeiGene | Study of Tislelizumab (BGB-A317) Versus Placebo in Combination With Chemoradiotherapy in Participant With ESCC

A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma

Beigene Study ID

BGB-A317-311

ClinicalTrials.gov ID

NCT03957590

China Drug Trials ID

CTR20190198

Study Overview

Sex: All

Age: 18 Years / 75 Years

No Study Documents

Study Overview

Sex: All

Age: 18 Years / 75 Years

No Study Documents